Pages with the fewest revisions
Jump to navigation
Jump to search
Showing below up to 50 results in range #1 to #50.
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)
- Clobetasol (1 revision)
- Trimetrexate (Neutrexin) (1 revision)
- Rituximab-rixi (Riximyo) (1 revision)
- Carbasalate calcium (Ascal) (1 revision)
- Rituximab-blit (Blitzima) (1 revision)
- University of Cincinnati Medical Center Hematology Oncology Fellowship (1 revision)
- Clonazepam (Klonopin) (1 revision)
- Dinutuximab beta (Qarziba) (1 revision)
- Rituximab-rite (Ritemvia) (1 revision)
- Meningioma - null regimens (1 revision)
- BE-CAR7 (1 revision)
- Hydroxyzine (Atarax) (1 revision)
- Sodium bicarbonate (1 revision)
- Rituximab-rixa (Rixathon) (1 revision)
- Long-Term Data Reinforce Standard of Care in Unresectable Melanoma (1 revision)
- Erythromycin (1 revision)
- Hepatic veno-occlusive disease - null regimens (1 revision)
- Fosnetupitant (Arokaris) (1 revision)
- Simvastatin (Zocor) (1 revision)
- Bevacizumab-onbe (Onbevzi) (1 revision)
- Ethinylestradiol (1 revision)
- Mitomycin pyelocalyceal (Jelmyto) (1 revision)
- Borofalan-10B (Steboronine) (1 revision)
- Philosophy (1 revision)
- Smoldering multiple myeloma - null regimens (1 revision)
- Lasofoxifene (Fablyn) (1 revision)
- Trastuzumab-herw (Herwenda) (1 revision)
- Germ cell tumor (1 revision)
- Oblimersen (Genasense) (1 revision)
- Trastuzumab-zerc (Zercepac) (1 revision)
- Cephalexin (Keflex) (1 revision)
- Tarlatamab (AMG-757) (1 revision)
- Danicopan (ALXN-2040) (1 revision)
- Cefixime (Suprax) (1 revision)
- Tenosynovial giant cell tumor - null regimens (1 revision)
- Penicillin V (1 revision)
- Bevacizumab-equi (Equidacent) (1 revision)
- Donafenib (Zepsun) (1 revision)
- Hereditary hemorrhagic telangiectasia - null regimens (1 revision)
- Thiotepa (Tepadina) (1 revision)
- Nogapendekin alfa inbakicept (Anktiva) (1 revision)
- Vonoprazan (Takecab) (1 revision)
- Patient assistance programs (1 revision)
- Cutaneous squamous cell carcinoma - null regimens (1 revision)
- Repotrectinib (Augtyro) (1 revision)
- Testosterone cypionate (1 revision)
- Autologous stem cells (1 revision)
- Aumolertinib (Amelie) (1 revision)
- Georgetown University Hospital Hematology Oncology Fellowship (1 revision)
- Allogeneic stem cells (1 revision)